Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

Calogero, Armando; Sagnelli, Caterina; Creta, Massimiliano; Angeletti, Silvia; Peluso, G.; Incollingo, Paola; Cândida, Maria; Minieri, Gianluca; Carlomagno, Nicola; Dodaro, Concetta Anna; Ciccozzi, Massimo

doi:10.1155/2019/4674560

Cited by 18 publications

(10 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays EUS is considered very accurate for T staging, because it can precisely define the degree of tumor penetration into the various layers of the rectal wall [37, 38, 39, 40, 41]. MRI is the best method to define distance of the mesorectal fascia from the lateral margin of the tumor and so to determine which patients can benefit from neoadjuvant therapy.…”

Section: Resultsmentioning

confidence: 99%

Colorectal cancer in the elderly patient: the role of neo-adjuvant therapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

AbstractBackgroundNeoadjuvant chemoradiotherapy has a significant role in downstaging cancer. It improves the local control of the disease and can make conservative resection of rectal cancer possible.MethodsWe enrolled 114 patients with subperitoneal rectal cancer who underwent neoadjuvant chemoradio-therapy and radical excision with total mesorectal excision (TME). The primary endpoint was oncological outcomes and the secondary endpoint was surgical outcomes.We evaluate the experience of a multidisciplinary team and the role of neoadjuvant chemoradiotherapy in integrated treatment of cancer of the subperitoneal rectum.ResultsSurgical procedures performed were abdominal perineal resection in 4 cases (3.5%), anterior resection in 89 cases (78%), Hartmann’s procedure in 5 cases (4.4%), and ultralow resection with coloanal anastomosis and diverting stoma in 16 patients (14%).Local recurrence occurred in 6 patients (5.2%), the overall survival was 71.9% at 5 years and disease-free survival was about 60%.ConclusionsThe effect of pathological downstaging amounted to 58.8%, including cPR. The pathologic complete remission occurred in 8.8% of cases.The outcomes of neoadjuvant therapy can be achieved when this treatment is associated with correct surgical technique with TME and the prognosis is defined by an anatomopathological examination performed according to Quirke’s protocol.

show abstract

Section: Resultsmentioning

confidence: 99%

Colorectal cancer in the elderly patient: the role of neo-adjuvant therapy

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Complications after a transplant can be related to the surgery itself (infection or abscess) or immunosuppressive therapy that the patient must continue for the life (cytomegalovirus [CMV] or viral infections) [5][6][7][8].…”

Section: Complications Related To Kidney Transplantationmentioning

confidence: 99%

Gastroenterological complications in kidney transplant patients

et al. 2020

Self Cite

View full text Add to dashboard Cite

Kidney transplantation is the surgical operation by which one of the two original kidneys is replaced with another healthy one donated by a compatible individual. In most cases, donors are recently deceased. There is the possibility of withdrawing a kidney from a consenting living subject. Usually, living donors are direct family members, but they could be volunteers completely unrelated to the recipient. A much-feared complication in case of kidney transplantation is the appearance of infections. These tend to arise due to immune-suppressor drugs administered as anti-rejection therapy. In this review, we describe the gastrointestinal complications that can occur in subjects undergoing renal transplantation associated with secondary pathogenic microorganisms or due to mechanical injury during surgery or to metabolic or organic toxicity correlated to anti-rejection therapy. Some of these complications may compromise the quality of life or pose a significant risk of mortality; fortunately, many of them can be prevented and treated without the stopping the immunosuppression, thus avoiding the patient being exposed to the risk of rejection episodes.

show abstract

“…HBV is considered an oncogenic virus, but its carcinogenic action is the result of its interaction with the presence of cirrhosis and with the host immune system[7,9,10,57-64]. In the absence of specific treatments, HBsAg positive cirrhotic patients develop HCC at a rate of about 2% per year in western countries and 3% in eastern countries[49].…”

Section: Hbv Infection: Pivotal Conceptsmentioning

confidence: 99%

Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention

Sagnelli

Pisaturo

Calò

et al. 2019

WJG

Self Cite

View full text Add to dashboard Cite

Reactivation of hepatitis B virus (HBV) replication is characterized by increased HBV-DNA serum values of about 1 log or by HBV DNA turning positive if previously undetectable in serum, possibly associated with liver damage and seldom life-threatening. Due to HBV reactivation, hepatitis B surface antigen (HBsAg)-negative/anti-HBc-positive subjects may revert to HBsAg-positive. In patients with hemo-lymphoproliferative disease, the frequency of HBV reactivation depends on the type of lymphoproliferative disorder, the individual's HBV serological status and the potency and duration of immunosuppression. In particular, it occurs in 10%-50% of the HBsAg-positive and in 2%-25% of the HBsAg- negative/anti-HBc-positive, the highest incidences being registered in patients receiving rituximab-based therapy. HBV reactivation can be prevented by accurate screening of patients at risk and by a pharmacological prophylaxis with anti-HBV nucleo(t)sides starting 2-3 wk before the beginning of immunosuppressive treatment and covering the entire period of administration of immunosuppressive drugs and a long subsequent period, the duration of which depends substantially on the degree of immunodepression achieved. Patients with significant HBV replication before immunosuppressive therapy should receive anti-HBV nucleo(t)sides as a long-term (may be life-long) treatment. This review article is mainly directed to doctors engaged every day in the treatment of patients with onco-lymphoproliferative diseases, so that they can broaden their knowledge on HBV infection and on its reactivation induced by the drugs with high immunosuppressive potential that they use in the care of their patients.

show abstract

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients

Cited by 18 publications

References 101 publications

Colorectal cancer in the elderly patient: the role of neo-adjuvant therapy

Colorectal cancer in the elderly patient: the role of neo-adjuvant therapy

Gastroenterological complications in kidney transplant patients

Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention

Contact Info

Product

Resources

About